Zachary Yablon, MD
Nephrology · Fort Lauderdale, FLNPI 1679772396
Payments from drug & device makers
Across 526 payments — averaging $3171.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$477K
- Boehringer Ingelheim$467K
- GSK$398K
- AstraZeneca$221K
- Eli Lilly$55K
- Merck$33K
- plus $17K from 28 others
Across 3 payments — averaging $15,485 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$46K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 4 | $477,264 |
| Boehringer Ingelheim | 18 | $466,743 |
| GSK | 82 | $398,038 |
| AstraZeneca(2 entities) | 126 | $220,586 |
| Eli Lilly | 2 | $55,103 |
| Merck | 2 | $33,285 |
| Boehringer Ingelheim International GmbH | 4 | $9,758 |
| Novartis | 5 | $1,363 |
| Amgen(2 entities) | 75 | $1,252 |
| Mallinckrodt Hospital Products Inc. | 43 | $943 |
| OPKO Pharmaceuticals, LLC | 32 | $715 |
| Bayer | 23 | $555 |
| Vifor Pharma, Inc. | 18 | $353 |
| Otsuka America Pharmaceutical, Inc. | 17 | $344 |
| Calliditas Therapeutics US Inc. | 12 | $328 |
| Travere Therapeutics, Inc. | 10 | $328 |
| Akebia Therapeutics Inc | 12 | $264 |
| ANI Pharmaceuticals, Inc. | 9 | $229 |
| Aurinia Pharma U.S., Inc. | 8 | $174 |
| Novo Nordisk | 4 | $72 |
| Outset Medical Inc | 1 | $72 |
| Mallinckrodt Enterprises LLC | 2 | $52 |
| Kyowa Kirin, Inc. | 2 | $48 |
| Fresenius USA Marketing, Inc. | 3 | $46 |
| Baxter Healthcare | 2 | $42 |
| Shire North American Group Inc | 2 | $40 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Ardelyx, Inc. | 1 | $23 |
| Sanofi | 1 | $22 |
| Shield Therapeutics Inc | 1 | $19 |
| La Jolla Pharmaceutical Company | 1 | $18 |
| Cumberland Pharmaceuticals, Inc. | 1 | $17 |
| Cormedix Inc. | 1 | $14 |
How this compares
$1,668,161 in reported general payments places this provider in the 95th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Fort Lauderdale
- Wayne KotzkerFort Lauderdale$3.4M
- Carlos BejarFort Lauderdale$530K
- Ryan LamarcaFort Lauderdale$361K
- Thomas MarburyOrlando$41.1M
- Julio VijilHollywood$16.1M
- Steven ZeigHollywood$14.3M
- Oscar GalvezMiami$14.2M
- Jesus NavarroTampa$13.3M
- Arvind MadanOrlando$9.7M
- David HalpertAtlantis$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.